Gracell Biotechnologies Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRCL research report →
About the company
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma.
- CEO
- Wei Cao BM,
- IPO
- 2021
- Employees
- 314
- HQ
- Suzhou, CN
Price Chart
- Market Cap
- $197.97M
- P/E
- -1.55
- P/S
- 0.00
- P/B
- 0.68
- EV/EBITDA
- -0.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.93%
- ROIC
- -39.90%
- Revenue
- $0 · -100.00%
- Net Income
- $-607,509,000 · -30.40%
- EPS
- $-44.85 · -26.69%
- Op Income
- $-624,658,000
- FCF YoY
- -907.12%
- 52W High
- $10.44
- 52W Low
- $1.40
- 50D MA
- $9.13
- 200D MA
- $5.01
- Beta
- -0.34
- Avg Volume
- 1.46M
Get TickerSpark's AI analysis on GRCL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GRCL coverage
Recent articles, reports, and earnings notes.
No research on GRCL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRCL report →Similar companies
Peers in the same neighborhood.